作为项目负责人承担和主持了多项省部级科研课题。参加了863重大专项课题。

作为全国主要研究者（leading PI）牵头多项全国多中心临床试验，并承接了多个单中心新药1-3期临床试验，涵盖以消化道肿瘤为主的实体肿瘤,致力于PD-1/PD-L1抗体、溶瘤病毒等免疫治疗新药及化疗药物在消化系统肿瘤的探索。

近6年以第一作者或通讯作者发表的代表性主要SCI论文：

1.       Huang J, Xu J, Chen Y, etal. Camrelizumab versus investigator's choice of chemotherapy as second-linetherapy for advanced or metastatic oesophageal squamous cell carcinoma(ESCORT): a multicentre, randomised, open-label, phase 3 study. LancetOncology. 2020, Jun;21(6):832-842. （IF 33.75）

2.       Zhang B, Wang X, Li Q, Mo H, Wang X, Song Y, Xu J, Qu T, HuangJ. Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1antibody in patients with advanced esophageal squamous cell carcinoma. Chin JCancer Res 2019;31(6):910-917.

3.       Huang J, Mo H, Zhang W, et al. Promising efficacy of SHR-1210, a novelanti-programmed cell death 1 antibody, in patients with advanced gastric andgastroesophageal junction cancer in China[J]. Cancer, 2019, 125(5):742-749.

4.       Huang J, Xu B, Liu Y, et al. Irinotecan plus S-1 versus S-1 in patientswith previously treated recurrent or metastatic esophageal cancer (ESWN 01): aprospective randomized, multicenter, open-labeled phase 3 trial[J]. CancerCommun (Lond), 2019, 39(1):16.

5.       Wang X, Zhang B, Chen X,  Mo H,  Wu D,  Lan B,  Li Q, Xu B, Huang J. Lactatedehydrogenase and baseline markers associated with clinical outcomes ofadvanced esophageal squamous cell carcinoma patients treated with camrelizumab(SHR-1210), a novel anti-PD-1 antibody[J]. Thorac Cancer, 2019,10(6):1395-1401.

6.       Huang J, Xu B, Mo H, et al. Safety, Activity, and Biomarkers ofSHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced EsophagealCarcinoma[J]. Clinical Cancer Research : an official journal of the AmericanAssociation for Cancer Research, 2018, 24(6):1296-1304.

7.       Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity,and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advancedsolid tumours: a dose-escalation, phase 1 study[J]. British Journal of Cancer,2018, 119(5):538-545.

8.       Zhang L, Li W, Lyu X, Song Y, Mao Y, Wang S, Huang J.Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positivethoracic esophageal squamous cell carcinoma[J]. Chin J Cancer Res, 2017,29(2):149-155.

9.       Wang W, Huang J, Tao Y, et al. Phase II and UGT1A1Polymorphism Study of Two Different Irinotecan Dosages Combined with Cisplatinas First-Line Therapy for Advanced Gastric Cancer[J]. Chemotherapy, 2016,61(4):197-203.

10.   Wang X, Niu H, Fan Q, Lu P,  Ma C , LiuW, Liu Y，Li W，Hu S，Ling Y，Guo L, Ying J, Huang J.Predictive value of EGFR overexpression and gene amplification on icotinibefficacy in patients with advanced esophageal squamous cell carcinoma[J].Oncotarget, 2016, 7(17):24744-24751.

11.   Zhou H, Song Y, Jiang J, Niu H, Zhao H, Liang J, Su H, Wang Z, ZhouZ, Huang J. A pilot phase II study of neoadjuvant triplet chemotherapyregimen in patients with locally advanced resectable colon cancer[J]. Chin JCancer Res, 2016, 28(6):598-605.

12.   Wang X, Wang X, Huang J. Irinotecan plusfluorouracil-based regimen as second or third-line chemotherapy for recurrentor metastatic esophageal squamous cell carcinoma[J]. Thorac Cancer, 2016,7(2):246-250.

13.   Huang J, Fan Q, Lu P, et al. Icotinib in Patients with PretreatedAdvanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFRGene Amplification: A Single-Arm, Multicenter Phase 2 Study[J]. J Thorac Oncol,2016, 11(6):910-917.

14.   Song Y, Huang J, Shan L, et al. Analyses of PotentialPredictive Markers and Response to Targeted Therapy in Patients with AdvancedClear-cell Renal Cell Carcinoma[J]. Chin Med J (Engl), 2015, 128(15):2026-2033.

15.   Lyu X, Huang J, Mao Y, et al. Adjuvant chemotherapy afteresophagectomy: is there a role in the treatment of the lymph node positivethoracic esophageal squamous cell carcinoma?[J]. J Surg Oncol, 2014,110(7):864-868.